Beta Drugs Limited

NSEI:BETA Stok Raporu

Piyasa değeri: ₹20.8b

Beta Drugs Yönetim

Yönetim kriter kontrolleri 4/4

Beta Drugs CEO'su Rahul Batra, Jan2021 tarihinde atandı, in görev süresi 3.83 yıldır. in toplam yıllık tazminatı ₹ 12.10M olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.41% ine doğrudan sahiptir ve bu hisseler ₹ 85.65M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 7.3 yıldır.

Anahtar bilgiler

Rahul Batra

İcra Kurulu Başkanı

₹12.1m

Toplam tazminat

CEO maaş yüzdesi100.0%
CEO görev süresi3.8yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi7.3yrs

Son yönetim güncellemeleri

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

CEO Tazminat Analizi

Rahul Batra'un ücretlendirmesi Beta Drugs'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

₹410m

Jun 30 2024n/an/a

₹387m

Mar 31 2024₹12m₹12m

₹364m

Dec 31 2023n/an/a

₹356m

Sep 30 2023n/an/a

₹348m

Jun 30 2023n/an/a

₹327m

Mar 31 2023₹12mn/a

₹307m

Dec 31 2022n/an/a

₹298m

Sep 30 2022n/an/a

₹289m

Jun 30 2022n/an/a

₹269m

Mar 31 2022₹8m₹8m

₹248m

Dec 31 2021n/an/a

₹216m

Sep 30 2021n/an/a

₹183m

Jun 30 2021n/an/a

₹150m

Mar 31 2021₹6m₹6m

₹117m

Dec 31 2020n/an/a

₹106m

Sep 30 2020n/an/a

₹95m

Jun 30 2020n/an/a

₹94m

Mar 31 2020₹5m₹5m

₹94m

Sep 30 2019n/an/a

₹97m

Jun 30 2019n/an/a

₹89m

Mar 31 2019₹1m₹1m

₹80m

Tazminat ve Piyasa: Rahul 'ın toplam tazminatı ($USD 143.42K ) Indian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 179.34K ).

Tazminat ve Kazançlar: Rahul 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Rahul Batra (41 yo)

3.8yrs

Görev süresi

₹12,100,000

Tazminat

Mr. Rahul Batra serves as the Chairman & Managing Director of Beta Drugs Limited since January 27, 2021. He had been Whole Time Director of Beta Drugs Limited since August 1, 2014 until January 27, 2021. H...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Rahul Batra
Chairman & MD3.8yrs₹12.10m0.41%
₹ 85.7m
Varun Batra
Joint MD & Whole Time Director3.8yrs₹12.10m0.35%
₹ 71.8m
Nipun Arora
Chief Financial Officer3.7yrs₹3.10mVeri yok
Rajni Brar
Company Secretary & Compliance Officer7.3yrs₹911.55kVeri yok
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director5.7yrs₹5.12mVeri yok
Seema Chopra
Whole Time Directorno data₹1.19mVeri yok
Sanjeev Chopra
Vice President of Technicalno dataVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

40.5yo

Ortalama Yaş

Deneyimli Yönetim: BETA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Rahul Batra
Chairman & MD10.3yrs₹12.10m0.41%
₹ 85.7m
Varun Batra
Joint MD & Whole Time Director10.3yrs₹12.10m0.35%
₹ 71.8m
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director2.8yrs₹5.12mVeri yok
Seema Chopra
Whole Time Director5.3yrs₹1.19mVeri yok
Manmohan Khanna
Independent Director7.3yrsVeri yokVeri yok
Rohit Parti
Independent Director7.3yrsVeri yokVeri yok

7.3yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BETA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).